Seres Therapeutics Inc (MCRB)

Dec 18, 2024

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat

Dec 18, 2024

Dec 17, 2024

Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference - Yahoo Finance

Dec 17, 2024

Dec 16, 2024

Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360

Dec 16, 2024

Dec 16, 2024

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - citybiz

Dec 16, 2024

Dec 16, 2024

Xilio Therapeutics Strengthens Leadership Team, Appoints Seres Therapeutics Veteran as Chief Legal Officer - StockTitan

Dec 16, 2024

Dec 16, 2024

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference - The Manila Times

Dec 16, 2024

Dec 16, 2024

Seres Therapeutics' Breakthrough Therapy Cuts Infection Risk by 77% in Stem Cell Transplants - StockTitan

Dec 16, 2024

Dec 11, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders - The Eastern Progress Online

Dec 11, 2024

Dec 10, 2024

Seres’ SER-155 gains breakthrough status for BSIs reduction - Yahoo Finance

Dec 10, 2024

Dec 09, 2024

MCRBSeres Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Dec 09, 2024

Dec 09, 2024

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) - The Manila Times

Dec 09, 2024

Dec 09, 2024

FDA Grants Breakthrough Therapy Designation to Seres - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

Seres' SER-155 Wins FDA Breakthrough Status After Stunning 77% Infection Reduction in Transplant Study - StockTitan

Dec 09, 2024

Nov 27, 2024

Seres Therapeutics (NASDAQ:MCRB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat

Nov 27, 2024

Nov 22, 2024

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - The Manila Times

Nov 22, 2024

Nov 22, 2024

Seres Therapeutics CEO to Present at Piper Sandler Healthcare Conference | MCRB Stock News - StockTitan

Nov 22, 2024

Nov 20, 2024

Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 By Investing.com - Investing.com Nigeria

Nov 20, 2024

Nov 20, 2024

Seres Therapeutics Q3 2024 Earnings Preview - MSN

Nov 20, 2024

Nov 20, 2024

Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 - Investing.com India

Nov 20, 2024

Nov 19, 2024

Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Rising Disease Prevalence Driving Revenue, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve

Nov 19, 2024

Nov 19, 2024

Seres Therapeutics chief legal officer sells shares worth $474 - Investing.com

Nov 19, 2024

Nov 19, 2024

Seres Therapeutics chief legal officer sells shares worth $474 By Investing.com - Investing.com Australia

Nov 19, 2024

Nov 19, 2024

Seres Therapeutics executive sells shares worth $397 - Investing.com

Nov 19, 2024

Nov 19, 2024

Seres Therapeutics executive sells shares worth $397 By Investing.com - Investing.com Canada

Nov 19, 2024

Nov 18, 2024

Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World

Nov 18, 2024

Nov 15, 2024

Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Canaccord Genuity Group Reiterates "Buy" Rating for Seres Therapeutics (NASDAQ:MCRB) - MarketBeat

Nov 14, 2024

Nov 14, 2024

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024

Nov 14, 2024

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... By GuruFocus - Investing.com Canada

Nov 14, 2024

Nov 14, 2024

Earnings call: Seres Therapeutics reports key Q3 2024 milestones - Investing.com

Nov 14, 2024

Nov 14, 2024

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

Seres Therapeutics Reports Q3 2024 Results and Strategic Progress - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres reports Q3 EPS from continuing operations (33c), consensus (24c) - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics expects cash to fund operations into Q4 of 2025 - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics: Q3 Earnings Snapshot - New Haven Register

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics reports Q3 EPS 58c, consensus (24c) - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

Nov 07, 2024

Seres Therapeutics (MCRB) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat

Nov 07, 2024

Nov 06, 2024

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 - The Manila Times

Nov 06, 2024

Nov 06, 2024

Seres Therapeutics Q3 2024 Earnings Call: MCRB Sets Key November Date | MCRB Stock News - StockTitan

Nov 06, 2024

Oct 30, 2024

Seres Therapeutics chief legal officer sells $2,939 in stock By Investing.com - Investing.com Australia

Oct 30, 2024

Oct 30, 2024

Seres Therapeutics exec von Moltke sells $2,991 in stock By Investing.com - Investing.com Canada

Oct 30, 2024

Oct 29, 2024

Seres Therapeutics executive sells shares worth $2,058 By Investing.com - Investing.com Canada

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics executive sells shares worth $2,058 - Investing.com India

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics executive sells stock for $2,749 By Investing.com - Investing.com Australia

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock - Investing.com India

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics chief legal officer sells $2,939 in stock - Investing.com India

Oct 29, 2024